Drug Trial Radar · NCT03363893
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
124
Actual
Start
Nov 14, 2017
Primary completion
Dec 15, 2022
Study completion Dec 15, 2022
Sponsor
- Lead sponsor
- Carrick Therapeutics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant groups with Triple Negative Breast Cancer (TNBC), Castrate Resistant Prostate Cancer (CRPC) and in combination with fulvestrant for patients with hormone receptor-positive (HR+ve) / human epidermal growth factor-2 negative (HER2-ve) breast cancer.
Conditions
- Advanced Solid Malignancies
Interventions
CT7001Drug
Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
FulvestrantDrug
Administered as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-Emergent Adverse Events and Laboratory Abnormalities (Safety and Tolerability)Time frame: Screening to end of study (28-35 calendar days after end of treatment). End of treatment at disease progression, unacceptable toxicity or withdrawal of consent. Average time on study 142.6 days (range 9 - 1135 days)
Locations
23 sites in 2 countries. Site status is shown where the registry gives one.
Research Site 54
Tucson, Arizona
Research Site 31
Beverly Hills, California
Research Site 37
Tampa, Florida
Research Site 38
Chicago, Illinois
Research Site 34
Boston, Massachusetts
Research Site 47
Cincinnati, Ohio
Research Site 39
Columbus, Ohio
Research Site 36
Portland, Oregon
Research Site 44
Austin, Texas
Research Site 46
Dallas, Texas
Research Site 48
Salt Lake City, Utah
Research Site 33
Salem, Virginia
Research site 11
Brighton, United Kingdom
Research site 5
Cambridge, United Kingdom
Research Site 7
Glasgow, United Kingdom
Research Site 10
Liverpool, United Kingdom
Research Site 9
London, United Kingdom
Research Site 8
London, United Kingdom
Research Site 3
London, United Kingdom
Research Site 1
Manchester, United Kingdom
Research Site 4
Manchester, United Kingdom
Research Site 2
Oxford, United Kingdom
Research Site 6
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.